BeiGene, Ltd. (BGNE) Financials
BGNE Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 5.8 billion | 2.2 billion |
2023-09-30 | 5.5 billion | 1.8 billion |
2023-06-30 | 5.7 billion | 1.9 billion |
2023-03-31 | 6.0 billion | 1.8 billion |
BGNE Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -388.5 million | 92.9 million |
2023-09-30 | -260.4 million | 96.0 million |
2023-06-30 | -415.4 million | 103.4 million |
2023-03-31 | -689.4 million | 75.3 million |
BGNE Net Income
No data available :(
BGNE Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 3.2 billion | - | 44.2 million |
2023-09-30 | 3.2 billion | - | 48.7 million |
2023-06-30 | 3.5 billion | - | 49.3 million |
2023-03-31 | 3.8 billion | - | 57.1 million |
BGNE Shares Outstanding
BGNE Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 166.9 million | 473.1 million | 416.5 million | - |
2023-09-30 | 182.3 million | 453.3 million | 364.4 million | - |
2023-06-30 | 121.5 million | 422.8 million | 395.0 million | - |
2023-03-31 | 125.6 million | 408.6 million | 328.5 million | - |
BGNE Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 634.4 million | 128.5 million |
2023-09-30 | 781.3 million | 96.3 million |
2023-06-30 | 595.3 million | 518.8 million |
2023-03-31 | 447.8 million | 81.8 million |
BGNE
Price: $153.58
52 week price:
Earnings Per Share: -8.45 USD
P/E Ratio: -16.01
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 346500
Ebitda: 116.2 millionMarket Capitalization: 15.1 billion